We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves First Treatment for Nonsmall-Cell Lung Cancer With Certain Mutation
FDA Approves First Treatment for Nonsmall-Cell Lung Cancer With Certain Mutation
For the first time, the FDA has approved a treatment for adult nonsmall-cell lung cancer (NSCLC) patients with a specific type of genetic mutation, giving Johnson & Johnson (J&J)’s Rybrevant the green light Friday.